Physician profile
Arbind Kumar
NPI 1851338636
$583.46
in general payments reported to CMS, 2019-2025
10 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.31 · 2020: $12.74 · 2022: $15.24 · 2023: $66.62 · 2024: $195 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.08 | 2019-2025 | |
| Gilead Sciences, INC. | $106.92 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $41.71 | 2025 | Voquezna |
| Genzyme Corporation | $30.52 | 2025 | |
| Exact Sciences Corporation | $25.99 | 2025 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $25.18 | 2024 | Resmetirom |
| Lilly USA, LLC | $21.91 | 2025 | Mounjaro, Zepbound |
| Ardelyx, INC. | $21.70 | 2024 | Ibsrela |
| Novo Nordisk INC | $18.87 | 2025 | Wegovy |
| Celltrion USA INC. | $13.58 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arbind Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.